195 related articles for article (PubMed ID: 22424640)
1. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Vitale A; Lombardi G; Ramirez Morales R; Cillo U
Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
[No Abstract] [Full Text] [Related]
2. Major achievements in hepatocellular carcinoma.
Bruix J; Llovet JM
Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
[No Abstract] [Full Text] [Related]
3. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
4. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Kim DY; Han KH
J Gastroenterol Hepatol; 2011 Nov; 26(11):1585-6. PubMed ID: 22011294
[No Abstract] [Full Text] [Related]
5. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
6. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
7. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Sinakos E; Dedes I; Papalavrentios L; Drevelegas A; Akriviadis E
Scand J Gastroenterol; 2010 Apr; 45(4):511-2. PubMed ID: 20113152
[No Abstract] [Full Text] [Related]
8. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Waidmann O; Hofmann WP; Zeuzem S; Trojan J
J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
[No Abstract] [Full Text] [Related]
9. TACE with or without systemic therapy?
Dufour JF
J Hepatol; 2012 Jun; 56(6):1224-5. PubMed ID: 22402292
[No Abstract] [Full Text] [Related]
10. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Di Maio M; Daniele B; Perrone F
Nat Rev Clin Oncol; 2009 Sep; 6(9):505-6. PubMed ID: 19707242
[No Abstract] [Full Text] [Related]
11. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
13. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Burak KW; Thomas MB; Zhu AX
HPB (Oxford); 2010 Jun; 12(5):321-2. PubMed ID: 20590906
[No Abstract] [Full Text] [Related]
14. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Yen Y; Zhou W
Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
[No Abstract] [Full Text] [Related]
15. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Vagefi PA; Hirose R
J Gastrointest Cancer; 2010 Dec; 41(4):217-20. PubMed ID: 20443078
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
Horgan AM; Dawson LA; Swaminath A; Knox JJ
J Gastrointest Cancer; 2012 Jun; 43(2):344-8. PubMed ID: 20683678
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
19. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
Toso C; Mentha G; Majno P
J Hepatol; 2013 Jul; 59(1):3-5. PubMed ID: 23567081
[No Abstract] [Full Text] [Related]
20. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
